Merck Animal Health Extends Commitment to Poultry Industry at XXV World Poultry Congress

Featuring Expert Symposium and Data on Optimizing Respiratory Protection
MADISON, N.J., August 30, 2016 – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced its participation in the XXV World Poultry Congress (WPC2016), including presentation of scientific data about improving bird health and performance, and an expert symposium to educate customers about approaches to protecting flocks from respiratory problems. The WPC2016 will be held in Beijing, China from September 5-9, 2016.
“Protecting flocks from respiratory disease is a major focus for our customers because it improves performance and reduces the reliance on antibiotics to treat disease. We are pleased to bring together experts to discuss the state of this disease area in Asia,” said Delair Bolis, global poultry business unit head, Merck Animal Health. “The WPC2016 provides a unique forum for sharing the latest scientific developments and best practices to support our customers in improving their businesses by ensuring the health and well-being of their birds.”
The symposium, “An Early Start on Respiratory Protection for a More Profitable Business,” will take place on Monday, September 5, from 10:00– 15:00, at the Intercontinental Beijing. Attendees who are interested in the symposium should contact their local Merck Animal Health sales representative.
Merck Animal Health will also present the following oral presentations:

  • Double Recombinant HVT-based Vaccines for Simultaneous Protection Against Newcastle Disease, Marek’s Disease and Infectious Laryngotrcheitis

Rik Koopman, DVM, global technical director, Merck Animal Health
Presentation 3-0189; Tuesday, September 6, 13:30-15:30 (Room 309B; S38)
Ease Vaccination Program with the Use of Next Generation HVT Recombinant Vaccines, Improving Bird Health and Performance
Rik Koopman, DVM, global technical director, Merck Animal Health
Presentation 3-0066; Thursday, September 8, 16:00-17:30 (Room 309B; S209)

  • Broiler Coccidiosis Vaccination: Performance of Flocks Using Vaccine Alone or As Part of Ionophore or Chemical Shuttle Program

Linnea Newman, DVM, global technical director, Merck Animal Health
Presentation 3-0080; Thursday, September 8, 16:00-17:30 (Room 309B; S210)

  • Proper Vaccination is Crucial to Optimize the Protection Expected from Vaccine/Vaccination Schedule

Denis Yau, DVM, Asia regional technical manager, Merck Animal Health
Presentation 3-0188; (Room 309B; S212)
Poster presentations include:

  • Sphereon® : a Novel Vaccine Formulation Technology for Storage and Preparation of Live Poultry Vaccines: the Case of the Nobilis® IB Primo QX Vaccine, Poster 3-0190
  • Serological Prevalence in Diseased Flock Exhibiting Immunosuppression & Respiratory Tract Infection, Poster 3-0094
  • IB PCR Survey in Thailand, Poster 3-0158
  • Review Poultry Respiratory Health Asia, Poster 3-0089
  • Review Poultry Intestinal Health Asia, Poster 3-009
  • Consistent Low MIC Enradin with Clostridium Perfrigens 2015, Poster 3-0106
  • Survey of Mycoplasma Synoviae Prevalence in the Middle East and North Africa Area, Poster 3-0046

For more information about the XXV World Poultry Congress, visit

About Merck Animal Health

For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (